Roxadustat
Anemia in Lower-Risk Myelodysplastic Syndrome (LR-MDS)
Phase 3Active
Key Facts
Indication
Anemia in Lower-Risk Myelodysplastic Syndrome (LR-MDS)
Phase
Phase 3
Status
Active
Company
About Kyntra Bio
Kyntra Bio is a private, pre-revenue biotech founded in 2021 and headquartered in Cambridge, Massachusetts. The company is developing a focused pipeline of innovative therapies, with its lead programs being roxadustat (Phase 3-ready for LR-MDS anemia) and FG-3246 (Phase 2 for mCRPC). Under CEO Thane Wettig, Kyntra leverages in-licensed assets and a platform-agnostic approach to target key biological pathways in cancer and anemia, with initial clinical data for its ADC expected in 2026.
View full company profile